NCT02846935View on ClinicalTrials.gov

p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

April 25, 2017

Primary Completion Date

January 22, 2018

Study Completion Date

January 22, 2018

Conditions
T-cell LymphomaAggressive B-cell LymphomaNon-Hodgkin's LymphomasIndolent B-cell Lymphoma
Interventions
DRUG

Decitabine

2-4 capsules depending on the weight of participant. Dec capsules are ingested \~60 minutes after THU capsules.

DRUG

Tetrahydrouridine

2-4 capsules depending on the weight of participant. Oral THU capsules followed 60 minutes later by oral Dec capsules are ingested 2X/week on consecutive days.

Trial Locations (1)

44195

Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
lead

Yogen Saunthararajah

OTHER

NCT02846935 - p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies | Biotech Hunter | Biotech Hunter